Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis
Chandra C Ghosh, Kristina Thamm, Anthony V Berghelli, Claudia Schrimpf, Manish R Maski, Tanaz Abid, Katelyn E Milam, Augustine Rajakumar, Ansgar Santel, Jan T Kielstein, Asif Ahmed, David Thickett, Keqin Wang, Maureen Chase, Michael W Donnino, William C Aird, Hermann Haller, Sascha David, Samir M Parikh, Chandra C Ghosh, Kristina Thamm, Anthony V Berghelli, Claudia Schrimpf, Manish R Maski, Tanaz Abid, Katelyn E Milam, Augustine Rajakumar, Ansgar Santel, Jan T Kielstein, Asif Ahmed, David Thickett, Keqin Wang, Maureen Chase, Michael W Donnino, William C Aird, Hermann Haller, Sascha David, Samir M Parikh
Abstract
Objective: The recent withdrawal of a targeted sepsis therapy has diminished pharmaceutical enthusiasm for developing novel drugs for the treatment of sepsis. Angiopoietin-2 is an endothelial-derived protein that potentiates vascular inflammation and leakage and may be involved in sepsis pathogenesis. We screened approved compounds for putative inhibitors of angiopoietin-2 production and investigated underlying molecular mechanisms.
Design: Laboratory and animal research plus prospective placebo-controlled randomized controlled trial (NCT00529139) and retrospective analysis (NCT00676897).
Setting: Research laboratories of Hannover Medical School and Harvard Medical School.
Patients: Septic patients/C57Bl/6 mice and human endothelial cells.
Interventions: Food and Drug Administration-approved library screening.
Measurements and main results: In a cell-based screen of more than 650 Food and Drug Administration-approved compounds, we identified multiple members of the 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor drug class (referred to as statins) that suppressed angiopoietin-2. Simvastatin inhibited 3-hydroxy-3-methyl-glutaryl-CoA reductase, which in turn activated PI3K-kinase. Downstream of this signaling, PI3K-dependent phosphorylation of the transcription factor Foxo1 at key amino acids inhibited its ability to shuttle to the nucleus and bind cis-elements in the angiopoietin-2 promoter. In septic mice, transient inhibition of angiopoietin-2 expression by liposomal siRNA in vivo improved absolute survival by 50%. Simvastatin had a similar effect, but the combination of angiopoietin-2 siRNA and simvastatin showed no additive benefit. To verify the link between statins and angiopoietin-2 in humans, we performed a pilot matched case-control study and a small randomized placebo-controlled trial demonstrating beneficial effects on angiopoietin-2.
Conclusions: 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors may operate through a novel Foxo1-angiopoietin-2 mechanism to suppress de novo production of angiopoietin-2 and thereby ameliorate manifestations of sepsis. Given angiopoietin-2's dual role as a biomarker and candidate disease mediator, early serum angiopoietin-2 measurement may serve as a stratification tool for future trials of drugs targeting vascular leakage.
Conflict of interest statement
The remaining authors have disclosed that they do not have any potential conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f3.jpg)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f4.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f5.jpg)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f6.jpg)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4806531/bin/nihms768690f7.jpg)
Source: PubMed